Business Context and Reporting Period
This Form 8-K reports on events occurring on October 13, 2017, when Altimmune, Inc. held its 2017 Annual Meeting of Stockholders. The filing details the approval of amendments to the Company's Certificate of Incorporation and Bylaws, as well as the results of various stockholder proposals.
Key Financial Metrics
This filing is a current report regarding corporate governance and stockholder votes. It does not provide financial data such as revenue, profit, cash flow, margins, debt, or liquidity. Investors should refer to the Company's most recent Form 10-K or 10-Q for financial performance metrics.
Material Changes and Governance Amendments
Stockholders approved several material amendments to the Company's governing documents:
- Anti-Takeover Provision: Adoption of Section 203 of the Delaware General Corporation Law (DGCL).
- Written Consent: Elimination of the ability for stockholders to act by written consent.
- Board Vacancies: Authorization for the Board of Directors to fill vacancies on the Board.
- Indemnification: Granting the Board flexibility to determine indemnification on a case-by-case basis for non-officer/director personnel.
- Bylaws Update: Reduction of the threshold for director removal from 75% to a majority of outstanding shares entitled to vote.
Voting Results and Stockholder Matters
The 2017 Annual Meeting saw 13,149,360 shares present or represented by proxy, representing 84.3% of issued and outstanding shares entitled to vote. Key voting outcomes include:
- Director Elections: All seven nominees (William J. Enright, David J. Drutz, John M. Gill, Philip L. Hodges, Mitchel B. Sayare, Klaus O. Schafer, and Derace L. Schaffer) were elected with significant "For" votes ranging from approximately 9.66 million to 9.72 million.
- Accounting Firm: Ratification of Ernst & Young LLP as the independent registered public accounting firm (13,099,774 For vs. 36,231 Against).
- Executive Compensation: The "say-on-pay" proposal passed (9,617,023 For vs. 103,460 Against). Stockholders voted to hold future advisory votes on compensation on an annual basis.
- Capital Structure: Approval of the issuance of shares underlying Series B Convertible Preferred Stock and related Warrants to comply with Nasdaq Listing Rules (9,739,871 For vs. 108,903 Against).
Investor Verification Checklist
- Verify the effective date of the Amended and Restated Certificate of Incorporation (filed October 17, 2017).
- Review the definitive Proxy Statement (Schedule 14A filed September 1, 2017) for detailed descriptions of the governance amendments.
- Confirm the terms of the Securities Purchase Agreement dated August 16, 2017, regarding the Series B Convertible Preferred Stock and Warrants approved in Proposal No. 10.
- Check subsequent filings for the actual issuance of shares related to the Series B Convertible Preferred Stock.